Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page adds new June 2026 press releases (Enhertu EU approval, Efzimfotase alfa trial results, Datroway CHMP recommendation) and removes older US approvals (Imfinzi, Datroway), aligning the listing with current company news.
    Difference
    5%
    Check dated 2026-06-29T10:55:18.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A new press release entry dated 15 June 2026 about Ultomiris being granted Priority Review in the US for immunoglobulin A nephropathy was added to the press releases. The 22 May 2026 entry about Enhertu being recommended for EU approval by CHMP was removed from the list.
    Difference
    0.9%
    Check dated 2026-06-22T05:25:16.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    Two new press releases were added: Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer (12 June 2026) and Elecoglipron moves to Phase III programme (08 June 2026). Several previously listed items were removed from the press releases listing, including Camizestrant in combination with a CDK4/6 inhibitor recommended for EU approval, the ASCO 2026 data showcase note, and an email entry (22 May 2026).
    Difference
    5%
    Check dated 2026-06-15T05:33:50.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    New press releases have been added to the Media Centre, highlighting recent trial results and product updates, including Ultomiris I CAN Phase III results (06 Jun 2026) and Camizestrant SERENA-6 updates (02 Jun 2026). Also, EMERALD-3 trial findings for Imfinzi/Imjudo with lenvatinib and TACE (01 Jun 2026) are now listed.
    Difference
    4%
    Check dated 2026-06-08T03:47:50.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    New press release entries were added for CARES Phase III results, Imfinzi approval for BCG-naïve high-risk non-muscle-invasive bladder cancer, and SERENA-6/camizestrant updates; older items CALYPSO and FDA advisory committee vote updates were removed from the listing.
    Difference
    4%
    Check dated 2026-06-01T01:14:19.000Z thumbnail image
  7. Check
    46 days ago
    Change Detected
    Summary
    New press releases have been added highlighting regulatory approvals and major presentations (Datroway US approval as a first-in-class TROP2 ADC; EU CHMP recommendations for Enhertu and Camizestrant; ASCO 2026 data showcase; Baxfendy US approval), while older entries from Q1 and several April 2026 releases have been removed from the listing.
    Difference
    5%
    Check dated 2026-05-24T14:25:16.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.